Caligan Partners LP

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Caligan Partners LP
CRD #289887
SEC #801-113810
CIK #0001727492
AUM 1,299.7 M (2026-05-29)
Employees 5 (60% Investors, 0% Brokers)
Fees
Minimum
Phone646-859-8204
Address780 Third Avenue
New York, NY 10017
Source [IAPD] [EDGAR] [Website] [LinkedIn]
Total AUM ($M)
1300104078052026002010201520212027
In the News
Wed, 20 May 2026 Caligan Partners reports Liquidia stock transfer worth $317,894 — Investing.com
Mon, 13 Apr 2026 List of Investments by Caligan Partners (Apr, 2026) — tracxn.com
Fees and Compensation — Form ADV Part 2A (5/29/2026) [Brochure]
Item 5: Fees and Compensation
Caligan provides investment advisory services to the Funds pursuant to separate investment
advisory or consulting agreements (the “Agreements”). The Agreements for the Funds set forth in
detail the fee structure relevant to the Funds.

Caligan or its affiliates receive compensation and fees from the Funds based on a percentage of
assets under management and based on performance. Such compensation and fee arrangements
are set forth in the Agreements. As set forth in the Agreements, fees and compensation paid to
the Adviser or its affiliates by the Funds are either deducted from the assets of the Funds, or
separately paid by the Fund or its affiliates; asset-based fees are generally deducted on a quarterly
basis and performance-based compensation is deducted at the times set forth in the Agreements.
The Adviser or its affiliates may waive, reduce, or calculate differently the asset-based fees and
performance-based compensation for certain Investors or Funds, including members, employees
and affiliates of the Adviser.

Investment Distributions
A Partnership’s governing documents detail the amount and priority of distributions made by the
Partnership to its Investors (the “Investment Distributions”). Investment Distributions will include:
net cash proceeds from the sale of investments or any portion of an investment or marketable
securities available for distribution, and cash receipts from dividends, interest and other non-tax
distributions from investments net of expenses (“Current Income”). Investment Distributions will
be net of performance-based fees as detailed in a Partnership’s governing documents.

Organizational Expenses
A Partnership will bear all costs and expenses incurred in connection with the organization of the
Partnership, its general partner and if applicable each parallel partnership, including legal and
accounting fees, printing costs, travel and out-of-pocket expenses, and all costs and expenses
incurred in connection with the offering of interests in the Partnership (“Organizational
Expenses”).

Operating Expenses
A Partnership will be responsible for all expenses relating to its own operations and if applicable
the operations of each parallel partnership, including without limitation:

    •      Expenses related to the research, due diligence and monitoring of actual and prospective
           investments (whether or not consummated) and the consummation of investments,
           including the following: brokerage, prime brokerage and futures commission merchant
           fees, commissions and expenses; expenses relating to short sales; clearing and settlement
           charges; custodial fees and expenses; bank service fees; interest expenses and fees related
           to financings or refinancings; fees and expenses of proxy research and voting services
           (including proxy solicitors, investment bankers, public relations experts, and costs
           associated with producing and distributing analyses and other materials); any
           compensation paid to individuals (other than individuals that are employees or partners of
           the Adviser) considered for nomination, nominated and/or appointed, to the board of a
           company in which the Partnership is or was invested (including any compensation paid in

Page | 5

           relation to serving in such capacity) and any related expenses (including costs incurred in
           connection with recruiting such persons), it being understood that, to the extent that such
           an individual is appointed to the board of such a company, it is generally expected that
           such compensation would not be considered a Partnership expense and would be borne by
           such company; fees and expenses of third-party professionals, including consultants,
           investment bankers, attorneys and accountants; experts or other consultants engaged to
           assist with an investment or prospective investment; investment and research-related travel
           expenses (which are travel expenses incurred by the Adviser or their affiliates related to
           the purchase or sale of, or due diligence regarding, the Partnership's investments, whether
           or not such investments are consummated, including lodging and meals); and the costs of
           any litigation or investigation involving activities of the Partnership.

    •      Operational expenses, including the following: fees and expenses relating to information
           technology hardware, software or other technology (including costs of software licensing,
           implementation, data management and recovery services and custom development) used
           to research investments, evaluate and manage risk, facilitate valuations, facilitate
           accounting functions, facilitate compliance with the rules of any self-regulatory
           organization or applicable law (including reporting obligations), facilitate and manage the
           order execution of financial instruments or otherwise manage the Partnership, such as
           Bloomberg terminals, portfolio management systems, risk management systems and order
           management systems; fees and expenses of third-party risk management products, models
           and services; third-party administrative fees and expenses; fees and expenses of third-party
           professionals, including consultants, valuation service providers, attorneys and
           accountants; third-party audit and tax preparation expenses; 100% of the cost of insurance,
           including premiums for cybersecurity insurance and liability insurance covering the
           Adviser and its affiliates, and the members, partners, officers, employees and agents of any
           of them; fees and expenses (including director registration fees) of the Partnership’s
...
Account Minimums and Types of Clients — Form ADV Part 2A (5/29/2026) [Brochure]
Item 7: Types of Clients
Caligan primarily provides discretionary investment management and advisory services to its
Funds directly. Investors may include high net worth individuals, partnerships, pension funds and
profit-sharing plans, trusts, estates, charitable organizations, corporations, business entities,
endowments, investment funds and foreign sovereign wealth funds. Investors will be required to
meet certain suitability qualifications to comply with applicable federal securities laws and
regulations, specifically as the Funds will rely on exemption 3(c)(7) of the Investment Company
Act.

A Partnership requires minimum initial subscriptions from Investors as described in its offering
documents. A Partnership may accept lower subscription amounts under the circumstances
described in its offering document.
Sector Form 13F Holdings Value ($M)
Liquidia Corp 306.4
Revolution Medicines Inc 183.0
Abivax Sa 162.8
Vaxcyte Inc 119.7
Xenon Pharmaceuticals Inc 81.0
Mineralys Therapeutics Inc 75.1
Exelixis Inc 66.6
CG Oncology Inc 60.9
BCTG Acquisition Corp 50.4
TYRA Biosciences Inc 48.9
View All
Holdings by Sector ($M)
1600128096064032002022202320252027
Type Form D Funds Date Sold AUM
HF Caligan Partners CV VII LP 2024-03-28
HF Caligan Partners CV VI LP [2024-03-28] 14.6 M 36.0 M
Filed 2024-05-17 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF Caligan Partners CV IV LP [2022-03-30] 18.2 M 175.6 M
Filed 2021-04-30 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF Caligan Partners CV V LP [2022-03-30] 18.2 M 9.6 M
Filed 2021-04-30 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF Caligan Partners Master Fund LP [2022-03-30] 6.9 M 812.0 M
Offered $6,946,060 · Filed 2025-08-15 (D/A) · Exemption 506(c) · Minimum $500,000 · Duration More than one year · Revenue $1,000,001 - $5,000,000
HF Caligan Partners CV III LP [2021-03-25] 33.9 M 42.2 M
Filed 2020-12-09 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF Caligan Partners CV II LP 2020-03-26 39.9 M
HF Caligan Partners CV I LP [2019-02-04] 19.0 M 23.8 M
Filed 2019-01-17 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
AUM Breakdown Accounts AUM ($M)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 8 1,299.7
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 8 1,299.7
By Discretionary
Discretionary 8 1,299.7
Non-Discretionary 0 0.0
Total 8 1,299.7
By Non-United States Persons
Non-United States Persons 666.7
United States Persons 633.0
Total 8 1,299.7
Form D Directors Role # Filings # Firms 2011 - 2026
Caligan Partners LP Promoter 6 2
Caligan Partners CV VI GP LLC Executive Officer 1 1
Samuel Merksamer Executive Officer 1 1
Caligan Partners CV IV GP LLC Executive Officer 1 1
Caligan Partners CV IV LP Promoter 1 1
Caligan Partners CV III GP LLC Executive Officer 1 1
Caligan Partners CV GP LLC Executive Officer 1 1
EDGAR Form CIK 2011 - 2026
13F-HR [0001727492]
3 [0001727492]
4 [0001727492]
SC 13D [0001727492]
SC 13G [0001727492]
Form 13D/13G Filer Form 13D/13G Subject Filed
Caligan Partners LP Sensei Biotherapeutics Inc [2026-05-15]
Caligan Partners LP LB Pharmaceuticals Inc [2026-05-15]
Caligan Partners LP Opus Genetics Inc [2026-05-15]
Caligan Partners LP SAB Biotherapeutics Inc [2026-05-15]
Caligan Partners LP Verrica Pharmaceuticals Inc [2025-11-24]
Caligan Partners LP Avalo Therapeutics Inc [2025-11-14]
Caligan Partners LP Evolus Inc [2025-08-14]
Caligan Partners LP Y-Mabs Therapeutics Inc [2025-05-14]
Caligan Partners LP Verrica Pharmaceuticals Inc [2025-02-12]
Caligan Partners LP Anika Therapeutics Inc [2023-08-17]
View All
Firm Profile (Form ADV)
ServesInstitutional, Retail
Fund TypesHedge Fund
LEI549300FWK7CGQ83RTY05
Form 3/4/5 Subject 2011 - 2026
Liquidia Corp
Caligan Partners LP
Johnson David Edward
Exelixis Inc
Verrica Pharmaceuticals Inc
Alimera Sciences Inc
Standard Biotools Inc
AMAG Pharmaceuticals Inc
Merksamer Samuel J
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Exelixis Inc EXEL
Common Stock
2025-11-25 Buy 27,532 $43.12 1,187,180
Liquidia Corp LQDA
"Common Stock, $0.001 par value per share (""Common Stock"")"
2025-06-17 Grant 18,396 $0.00
Exelixis Inc EXEL
Option (right to buy) · derivative
2025-05-29 Grant 21,464 $0.00
Alimera Sciences Inc ALIM
"Common Stock, par value $0.01 per share (""Common Stock"")"
2024-09-16 Other 16,835,154
Alimera Sciences Inc ALIM
Warrants · derivative
2024-09-16 Other 800,000
Alimera Sciences Inc ALIM
Notional Derivative Agreements (obligation to buy) · derivative
2024-09-16 Other 1
Liquidia Corp LQDA
"Common Stock, $0.001 par value per share (""Common Stock"")"
2024-09-12 Grant 1,123,595 $8.90 9,999,996
Liquidia Corp LQDA
Common Stock
2024-08-30 Sell 150,000 $9.51 1,426,500
Liquidia Corp LQDA
"Common Stock, $0.001 par value per share (""Common Stock"")"
2024-08-30 Other 3,440,948
Liquidia Corp LQDA
Common Stock
2024-08-30 Buy 150,000 $9.51 1,426,500
Liquidia Corp LQDA
"Common Stock, $0.001 par value per share (""Common Stock"")"
2024-06-20 Grant 20,359 $0.00
Exelixis Inc EXEL
Option (right to buy) · derivative
2024-05-31 Grant 42,767 $0.00
Exelixis Inc EXEL
Common Stock
2024-05-30 Buy 225,000 $20.76 4,671,000
Exelixis Inc EXEL
Common Stock
2024-05-28 Buy 200,000 $20.32 4,064,000
Exelixis Inc EXEL
Common Stock
2024-02-21 Buy 190,000 $20.70 3,933,000
Liquidia Corp LQDA
"Common Stock, $0.001 par value per share (""Common Stock"")"
2023-12-14 Buy 1,117,318 $7.16 7,999,997
Exelixis Inc EXEL
Common Stock
2023-11-27 Buy 120,409 $21.61 2,602,038
Exelixis Inc EXEL
Common Stock
2023-11-27 Sell 120,409 $21.61 2,602,038
Alimera Sciences Inc ALIM
Common Stock
2023-09-14 Buy 579,000 $3.39 1,962,810
Alimera Sciences Inc ALIM
Notional Derivative Agreements (obligation to buy) · derivative
2023-09-14 Other 1
showing 20 of 56 most recent transactions
Comparable Firms State AUM
Weatherbie Capital LLC
MA 1,343.1 M
Coury Firm Asset Management LLC
PA 1,324.8 M
Paragon Capital Management
CO 1,316.2 M
Savoie Capital LLC
IL 1,315.0 M
Synergy Asset Management LLC
WA 1,299.4 M
New Legacy Group LLC
NY 1,283.7 M
Private Capital Advisors Inc
CT 1,281.8 M
L2 Asset Management LLC
1,270.8 M
Zadig Asset Management Sa
1,252.2 M
Arbiter Partners Capital Management LLC
NY 1,250.7 M
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com